Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Novavax Investor Relations
14.06.2025 02:50
<ul><li>Both vaccine candidates induced robust immune responses across all antigens tested</li><li>No new safety signals were observed and both vaccine candidates were well tolerated consistent with … [+6369 chars]